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Objectives. To evaluate the influence of secondary infection on major amputation in chronic critical leg ischemia (CLI).
Design. Prospective, controlled observational study.
Materials and Methods. Sixty-seven patients with CLI and ischemic lesions participated in the study. Presence of
infection was defined by clinical, laboratory and radiological criteria. Patients were categorized as having no local infection,
soft tissue infection or osteomyelitis treated without antibiotics, amoxicillin/clavulanacid for 1 month or ciprofloxacin and
clindamycin for 3 months, respectively. Clinical outcome was assessed at 2, 6 and 12 months. Study endpoints were major
amputation and mortality. Analyses were performed using the Kaplan-Meier method.
Results. Forty-seven of 67 patients had a local infection. Major amputation was lower in patients with successful revas-
cularization as compared to patients unsuitable for or with failed (without) revascularization (0% vs 26%, p< 0.01). In
patients with successful revascularization the probability of complete healing was lower with secondary infection (23% vs
71%, p¼ 0.03). In patients without revascularization complete healing was rare (<10%), but secondary infection did not
influenced major amputation, mortality or serious adverse events.
Conclusion. Secondary infection reduces the likelihood of successful healing following revascularisation of CLI.
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Peripheral arterial disease (PAD) is a frequent cause of
morbidity in industrialized countries. The annual in-
cidence of PAD is 5e11 cases per 1000 subjects per
year in people over 40 years old.1 Twenty percentage
of subjects aged over 75 years have PAD,2 with 1e2%
of them developing critical leg ischemia (CLI) within
one year of follow up.3,4 CLI is defined as chronic
ischemic rest pain, ulcers, or gangrene attributed to
severe arterial occlusive disease.5 The majority of these
patients have ankle pressure below 50 mmHg and toe
pressure below 30 mmHg and require amputation in
the absence of successful revascularization. The
outcome of infections complicating critically ischemic
lesions is poorly investigated. In a retrospective study
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ischemic lesions was frequent (56%), and associated
with a significantly higher rate of all amputations.
This prospective single center observational study
was initiated to test the hypothesis that outcome of
patients with CLI and secondary infection is similar
to that of patients with CLI without infection. We pos-
tulated that secondary infection treated with anti-




Three hundred and fifty patients with CLI were seen
in our tertiary vascular referral centre between March
2000 and October 2003. To be included in the study,
patients needed to have CLI in combination with at
least one ischemic lesion present for more than 2erved.
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failure or malignancy; A decision not to carry out
primary amputation at study entry. CLI was defined
according to the Second European Consensus
Document.5 Overall 67 patients with CLI and ischemic
lesions qualified and agreed to participate in this pro-
spective 12-month observational study. Patients were
excluded from study participation due to the pre-
defined exclusion criteria (33.2%, n¼ 94), unwilling-
ness to participate (57.9%, n¼ 164), non-compliance
(6.7%, n¼ 19), and failure to attend for follow up
(2.1%, n¼ 6). The demographic data of participants
is shown in Table 1. The study protocol was approved
by the local institutional review board. All patients
gave written informed consent.
Study design
In this prospective observational study consecutive
patients with CLI were separated into a control group
and an infection group. Infection of an ischemic lesion
was suspected if two or more of the following criteria
were present: peripheral body temperature >37.5 C;
ischemic lesion characterized by redness, swelling
and pain; strong or putrid secretion; Cereactive pro-
tein (CRP) >5 g/l or leucocytes >10.000/ml; positive
probe to bone test (infection score). Ischemic lesions
with signs and symptoms of secondary infection
were evaluated using conventional X-ray and mag-
netic resonance imaging (MRI) to determine the pres-
ence of osteomyelitis.
A standardized, empiric antibiotics regime was pre-
scribed to all patients in the infection group. Patients
with soft tissue infection were treated with amoxicillin/
clavulonacid 1 g twice a day orally for 4weeks. Patients
with osteomyelitis verified by X-ray or MRI were
treated with ciprofloxacin 750 mg twice daily and clin-
damycin 300 mg three times daily orally for 12 weeks
(Fig. 1). All patients were evaluated by a team of
interventionalists and vascular surgeons for optimal
revascularization therapy on a case-by-case basis. Deci-
sions were based on urgency of clinical presentation,presence of co-morbidities and arterial anatomy. In
cases of prohibitive lesion pattern, patient’s refusal,
or if the overall clinical situation suggested an
expectant attitude, CLI was treated conservatively in-
cluding analgesic, antiplatelet/antithrombotic therapy
and infrequently prostaglandins.
Follow up
Clinical outcome was assessed at 2, 6 and 12 month
follow up. At each visit the ankle brachial index
(ABI), transcutaneous partial oxygen pressure
(tcpO2) measurement, and a photo documentation of
the lesions were performed. Patients were evaluated
for healing of lesions, minor or major amputations, ad-
verse events, and infectious complications. Endocardi-
tis, septicaemia andmultiorgan failure were defined as
serious adverse events associated with infection.
Blood samples for CRP and leucocytes were collected
at 2 and 12 months. Complete healing was defined
as continuous viable, epithelial covering of all lesions.
Successful revascularization was defined as an in-
crease of ABI >0.1 documented for at least 30 days.7
Amputation above the ankle was defined as major am-
putation. Minor amputation was defined as preserva-
tion of at least part of the foot, without requirement for
prosthesis. Technical inability, missing autologous
veins, high operation risk or disagreement of the
patient to undergo revascularization were reported
as unsuitable for revascularization. Documented re-
occlusion or failure to achieve ABI >0.1 were consid-
ered to represent failed revascularization. Failed and
unsuitable for revascularization were summarized as
without revascularization. Major amputation and
mortality were defined as study endpoints.
Statistical analysis
Continuous data are given as mean þ/ standard
deviation. For observation periods the median is
also noted. Odds ratio (OR) with the appropriate
95% confidence intervals (95% CI) were calculated toTable 1. Demographic data of patients (n[ 67) enrolled
Control group (n¼ 20) Infection group (n¼ 47) p-value
N (%) N (%)
Age (mean SD), y 74.8 8.0 74.3 12.9 NS
Creatinine (mean SD), mmol/l 105 41 108 34 NS
1 dialysis 3 dialysis
Men 12 (60) 31 (66) NS
Hypertension 16 (80) 33 (70) NS
Dyslipidaemia 8 (40) 18 (38) NS
Obesity (BMI> 25) 13 (65) 27 (57) NS
Smoking 11 (55) 28 (60) NS
Diabetes 10 (50) 26 (55) NS
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1g BID, 4 weeks
Ciprofloxacin 750 mg BID
Clindamycin 300 mg TID
12 weeks
No antibioticsX ray negative
Fig. 1. Standardized antibiotic treatment according to classification of patients.assess the relation between individual cardiovascular
risk factors and major amputation. Cumulative
mortality and major amputation rates were calculated
using the KaplaneMeier method. Statistical analysis
was performed using Stat View software (version
4.57;SAS,Cary, ND, USA) as well as Cochrane Group
software (OR). Differences achieving a p-value <0.05
were considered statistically significant.
Results
Mean follow up time for all patients was 331 (range 4
to 409) days. There was no statistically significant dif-
ference in demographic findings between control and
infection groups. Forty-seven of 67 patients were clas-
sified as having secondary local infection (70%), and
were enrolled in the infection group. Osteomyelitis
was confirmed in 26 of 47 patients in the infection
group (55%). All patients finished the intended, pre-
defined antibiotic treatment if enrolled in the infectiongroup. Twenty patients (30%) without signs of local
infection were assigned as control group.
In a univariate analysis there was no statistically
significant relation between major amputation and
cardiovascular risk factors present (Fig. 2). Diabetes
mellitus, renal failure, obesity and hypercholesterol-
emia did not influence major amputation rate. Out of
67 patients enrolled, there were 49 patients with revas-
cularization (Table 2). Sustained clinical and hemody-
namic success was achieved in 29 patients. In 18
(27%) patients neither catheter-based nor surgical reva-
scularization could be accomplished. Successful
revascularization had a significant influence on healing
of ischemic lesions (10/29 vs 2/38; p< 0.01), and on the
rate of major amputations (0/29 vs 10/38; p< 0.01).
The presence of an infection was significantly associ-
ated with a lower probability of complete healing as
compared to those lesions without signs and symp-
toms of infection (5/22 vs 5/7, p¼ 0.03; Table 3). Local
wound management differed, in that patients withFig. 2. Fixed odds ratios (OR) and 95% confidence intervals (95%CI) of cardiovascular risk factors present and major
amputations within 12-months follow up. n/N number of events/number of participants per group; RF risk factor.
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if needed and wet wound bandages, whereas lesions
in patients without or with failed revascularization
were decontaminated using antiseptic iodide tincture
and were kept as dry as possibly to allow demarcation.
In patients without revascularization, secondary infec-
tion did not influence major amputation, mortality or
serious adverse events (Table 3, Fig. 3). None of the
19 deaths was directly related to an infectious com-
plication, but was rather a consequence of the multi-
morbidity and high cardiovascular risk profile of
patients with CLI (Fig. 3).
Discussion
This prospective observational study emphasizes that
successful revascularization significantly reduces
major amputation and improves healing of ischemic
lesions in patients with CLI. Secondary infection of
ischemic lesions is associated with a lower probabil-
ity of complete healing suggesting that minor ampu-
tation without delay is recommendable in patients
with successful revascularization. Our study also
suggests that cardiovascular risk factors do not sig-
nificantly influence limb salvage if CLI is established.
This finding suggests that the prospect of limb
salvage is similarly poor in all patients with CLI
independent of whether a particular risk factor is
present or not.
Table 2. Revascularization procedures performed within 1 years of
follow up (49 patients)
Revascularization* All Infection Control
(n¼ 49) (n¼ 35) (n¼ 14)
Single surgical intervention 17 (25.4%) 9 (19.1%) 8 (40.0%)
Multiple surgical interventions 1 (1.5%) 0 (0%) 1 (5.0%)
Single catheter-based intervention 17 (25.4%) 16 (34.0%) 1 (5.0%)
Multiple catheter-based
interventions
9 (13.4%) 8 (17.0%) 1 (5.0%)
Combination of surgical and
catheter-based interventions
5 (7.5%) 2 (4.3%) 3 (15.0%)
* Several per patient possible.Secondary infection of ischemic lesions in patients
with CLI is not inevitably associated with major am-
putation or systemic complications if appropriately
treated with antibiotics. Treatment of CLI should im-
prove patient’s quality of life, decrease risk of adverse
events, and avoid dependence on institutional care
often needed after major amputation.8 Whether prog-
nosis can be improved by standardized antibiotic
therapy is unclear,6 but it is known that major ampu-
tation is associated with a significant longer hospital
stay, more costs, long-term institutional support and
lower quality of life.6,9e14
Results of the present observational study support
the hypothesis that secondary infection in revascular-
ized and non-revascularized patients with CLI can be
safely controlled by standardized, long-term antibiotic
therapy given that optimal wound care and maximal
possible revascularization is provided. Revascularisa-
tion in this serieswas primarily performed by endovas-
cular means. A differing approach to wound care is
needed in patients with as compared to those without
revascularization. As secondary infection of ischemic
lesions is associated with a lower probability of
complete healing, minor amputation without delay
should be considered in patients with successful
Fig. 3. Calculated cumulated survival rate of 67 patients en-
rolled according to revascularization status (with/without)
and group assignment (control/infection).Table 3. Clinical outcome of 67 patients with CLI
With successful revascularization* Without revascularization & failed revascularization*
Infection (n¼ 22) Control (n¼ 7) p-value Infection (n¼ 25) Control (n¼ 13) p-value
N (%) N (%) N (%) N (%)
Complete healing 5 (22.7) 5 (71.4) 0.03 2 (8.0) 0 NS
Minor amputation 6 (27.3) 1 (14.3) NS 2 (8.0) 1 (7.7) NS
Major amputation 0 0 NS 5 (20.0) 5 (38.5) NS
Persistent lesion 10 (45.5) 1 (14.3) NS 15 (60.0) 7 (53.8) NS
Death 7 (31.8) 0 NS 8 (32.0) 3 (23.1) NS
Unknown 1 (4.5) 0 NS 1 (4.0) 0 NS
NS not significant;
* Several per patient possible.
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care and immobility of the patients. Conservative,
non-surgical wound care is a justified safe option in
patients without revascularisation and persistence of
critical ischemia. Although lesions rarely heal, there
remains a chance of stabilisation and limb salvage.
The non-surgical approach is supported by Treiman
et al. who reported 91 cases with ischemic heel lesions,
non leading to infection related death in a study with
21 months follow-up.6,15 A trial published by Peterson
et al. showed that prolonged therapy with a single
broad-spectrum antimicrobial agent was successful in
patients with severe peripheral vascular disease. Sixty
percent of lesionswere free of infectionwithin 1-year of
follow-up, including patients with osteomyelitis.6,16 A
pilot study reported by Strecker et al. enrolled 10 pa-
tients with CLI (6 patients with osteomyelitis), intra-
arterial infusion of prostaglandin E1 and antibiotics
via a subcutaneous port was successful in reducing
ulcer size and induced ulcer healing in 4 patients
with osteomyelitis.6,17 In a retrospective study by Lep-
a¨ntalo et al. analyzing 95 patients with CLI unsuitable
for revascularization no more than 25% of patients
were alive with both legs preserved, and the rate of
major amputations was 46% at 1 year of follow up.6,18
Our study emphasizes the poor survival of patients
with a cumulative, calculated mortality of 28% at
1 year; 34% in the infection group, and 15% in the
control group, respectively. Although mortality was
higher in the infection group, this was not a direct
consequence of infectious complications even in those
patients with failed revascularization, but rather the
consequence of the multi-morbidity and pronounced
cardiovascular risk profile.
Several limitations of our study need to be men-
tioned. Antibiotic therapy was not randomized, so
we cannot exclude a decision bias. Wound care was
optimized for patients enrolled and gave more favour-
able results as compared with published series report-
ing higher amputation rates in CLI.18 Patients with
extended secondary infection, often considered for
primary amputation, were excluded from study entry.
Moreover, based on the inherent problem of low re-
cruitment of patients with CLI there might have been
a relevant selection bias in favour of low risk patients
as the majority of patients were excluded or refused to
participate in this prospective follow up study.
In conclusion, secondary infection of ischemic lesi-
ons in revascularized and non-revascularized patients
with CLI is not inevitably associated with major am-
putation or mortality if appropriately treated with
a standardized antibiotic treatment. Earlyminor ampu-
tation should be performed to avoid long-term wound
care and immobility in patients with successfulrevascularization. Conservative non-surgical wound
management is mandatory in patients without revas-
cularization and can safely be recommended even
with signs and symptoms of local infection.
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